对比剂温度和浓度对CT检查患者舒适度与安全性的影响:CATCHY II试验
该研究在马斯特里赫特大学医学中心+将2021年10月27日至2022年10月31日期间所有完成舒适度问卷的择期增强CT患者按1年分为4组,分别接受370 mg I/mL或300 mg I/mL对比剂在37°C预热或室温下注射。结果显示预热对比剂在患者舒适度和安全性方面不优于室温对比剂,且与对比剂浓度无关。
要点
- 预热对比剂在舒适度、疼痛感、外渗及过敏样反应方面与室温对比剂无显著差异。
- 热感和头晕在4组间有显著差异但效应量小,其余不良事件无显著差异。
- 冠状动脉CT血管成像中4组冠状动脉衰减无显著差异,门静脉期CT肝增强有显著差异。
核心结论
- 使用预热对比剂在患者舒适度和安全性方面不优于室温对比剂,与对比剂浓度无关;作者认为使用前预热对比剂不必要。
研究设计与样本
- 前瞻性研究,纳入2021年10月27日至2022年10月31日在马斯特里赫特大学医学中心+所有完成舒适度问卷的择期增强CT患者,按1年分为4组:组1(370 mg I/mL,37°C)、组2(370 mg I/mL,室温)、组3(300 mg I/mL,37°C)、组4(300 mg I/mL,室温)。
关键影像表现/征象
- 舒适度评分组间比较P=0.054,疼痛感P=0.469,外渗P=0.542,过敏样反应P=0.253,均无显著差异。
- 热感和头晕组间比较P分别为0.005和0.047,效应量小。
- 冠状动脉CT血管成像中4组冠状动脉衰减无显著差异(P=0.113)。
- 门静脉期CT扫描中4组肝增强有显著差异(P=0.008)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Previous research on the necessity to reduce the viscosity of contrast media (CM) by either prewarming CM before injection during computed tomography (CT) or by using less concentrated CM has yielded conflicting results. In addition, there is limited evidence on patient comfort.
OBJECTIVES: The aim of the study was to examine if prewarming CM, with varying CM concentrations, is superior to CM at room temperature, with respect to patient comfort and safety in CT.
MATERIALS AND METHODS: All elective patients scheduled for contrast-enhanced CT scans at Maastricht University Medical Center+ between October 27, 2021 and October 31, 2022 were eligible for inclusion when a questionnaire evaluating patient comfort was completed. This 1-year period was divided into 4 intervals (4 groups): group 1 (370 mg I/mL, 37°C), group 2 (370 mg I/mL, room temperature), group 3 (300 mg I/mL, 37°C), and group 4 (300 mg I/mL, room temperature). All CT scans were performed using state of the art equipment (Siemens Healthineers; SOMATOM Force and SOMATOM Definition AS, Forchheim, Germany). Contrast media injections were performed using a dual-head power injector (Stellant; Bayer Healthcare, Berlin, Germany) and individualized to body weight and/or tube voltage, depending on the CM protocols. After the CT scan, patients completed a questionnaire covering the primary outcomes comfort, pain, and adverse events such as feelings of heat, nausea, vomiting, itchiness, urticaria, difficulty breathing, dizziness, goosebumps, or an odd taste. Technicians were asked to report any adverse events, including extravasation and allergic-like reactions. The secondary outcome involved attenuation (in Hounsfield unit, HU), which was evaluated by assessing the HU of the coronary arteries for vascular CT, and liver enhancement in portal venous CT. The Kruskal-Wallis test was used for continuous scale outcomes and χ 2 tests for examining adverse events.
RESULTS: Results showed no significant differences examining comfort score ( P = 0.054), pain sensation ( P = 0.469), extravasation ( P = 0.542), or allergic-like reaction ( P = 0.253). Significant differences among the 4 groups were found with respect to heat sensation and dizziness ( P = 0.005 and P = 0.047, respectively), showing small effect sizes. All other adverse effects showed no significant results. No significant differences were observed in coronary attenuation among the 4 groups in coronary CT angiography ( P = 0.113). When analyzing attenuation in portal venous CT scans, significant differences were found among the 4 groups ( P = 0.008).
CONCLUSIONS: Administrating prewarmed CM is nonsuperior compared with CM at room temperature in relation to patient comfort and safety, regardless of CM concentration. These findings suggest that prewarming CM before usage is unnecessary, which will improve the efficiency of daily clinical workflow and brings environmentally friendly benefits.
引用
- Stammen L, Mihl C, Vandewall J, et al. Influence of Contrast Media Temperature and Concentration on Patient Comfort and Safety in Computed Tomography: CATCHY II Trial. Invest Radiol. 2024. PMID: 38240647. doi:10.1097/RLI.0000000000001063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。